– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters– The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities– T2DM phase 3 data readout is expected to be announced in the first half of 2025ROCKVILLE, MD and SHENZHEN, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. The publication reports results of the randomized, placebo-controlled 12-week study to assess efficacy, safety and tolerability of HTD1801 compared to placebo in patients with T2DM. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 12 with HTD1801 versus placebo. A majority of patients treated with HTD1801 achieved target HbA1c

CardCash Platform Provides Cost-Reduction Strategy for High-Demand Sports Tickets and Merchandise Ahead of 2025 Major League Baseball (MLB) SeasonPlatform Supports Savings on Popular Sports Retailers Including StubHub, Nike, Adidas, Under Armour, Dick's Sporting Goods, and FanaticsSchaumburg, Illinois, Mar 5, 2025 - (ACN Newswire via SeaPRwire.com) - Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the expansion of its CardCash.com platform into the high-margin sports retail sector, offering consumers smart saving solutions for sports fans to save on tickets, apparel and game-day essentials as part of the Company’s strategic growth initiative for 2025.With the 2025 MLB season getting underway, fans are facing rising costs for tickets, gear, and game-day essentials. The average cost of attending a baseball game has climbed to $152 for a family of four, with premium seats seeing increases as high as 38.8%. But CardCash.com, a leading secondary gift card exchange operated by Giftify, is stepping up to help fans save.By using discounted gift cards from StubHub, Nike, Adidas, Under Armour, Dick’s Sporting Goods, and Fanatics, families can cut costs on tickets, jerseys, and game-day snacks.For example, a family of four heading to a Yankees game this season, their tickets alone would cost over $300, but by paying with StubHub gift cards purchased at CardCash.com at an 11% discount, they save over $30. Grabbing team gear from MLB Shop? That's another 11% saved.Making Baseball More Affordable“With rising ticket prices, fans are looking for ways to save without missing out on their favorite teams,” said Carol Rosenblum, Marketing Manager at CardCash.com. “By using our discounted gift cards, baseball lovers can cut costs by 10-20%, whether they’re buying tickets, upgrading their game-day outfits, or picking up tailgating gear.”Spring Cleaning: Turn Unused Gift Cards into Game-Day CashThe CardCash.com platform offers a comprehensive solution for sports fans: not only can they purchase discounted gift cards to save on upcoming expenses, but they can also monetize unused gift cards by exchanging them for cash or store credit—creating a complete financial ecosystem for sports enthusiasts. Just as fans engage in spring cleaning around their homes, CardCash encourages them to clear out their wallets and drawers of forgotten gift cards and transform that untapped value into memorable sports experiences.“As MLB teams welcome fans back to stadiums across the nation, this is the perfect time for people to check their wallets, trade in unused gift cards, and put those funds toward experiences they’ll actually enjoy,” said Ketan Thakker, CEO of Giftify, Inc. “Why let old gift cards go to waste when they can help get you to the ballpark? This sports fan initiative represents a key component of our 2025 growth strategy to penetrate high-frequency consumer spending categories while building recurring engagement with our platform.”About Giftify, Inc.Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.Forward-Looking StatementsPress Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.Investors Contacts:IR@giftifyinc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."About MEndoBMicreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.About MicreosMicreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.For more information, visit www.micreos.com.About Northway BiotechNorthway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.For more information, please visit www.northwaybiotech.com.Micreos Contact:Matt ReganCEO and Board member, Micreos Pharmaceutical AGm.regan@micreos.comNorthway Biotech Contact:Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comContact InformationVladas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comSOURCE: Northway Biotech Copyright 2025 ACN Newswire via SeaPRwire.com.

LONDON, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - In a landmark event, the United Kingdom will host the Global Anti-Scam Summit (GASS) London 2025, bringing together an unprecedented number of policymakers, industry leaders, and cybersecurity experts. This summit, organized by the UK Home Office, Global Anti-Scam Alliance (GASA), Cifas, and Euroconsumers, is set to be the most significant anti-scam event to date, with a focus on forging global partnerships to address the rampant rise of online scams, which last year cost the global economy nearly US$1.03 trillion.Unveiling Global Strategies Against ScamsThe summit will kick off with keynote speeches from top international figures, including The Rt Hon Lord Hanson of Flint, who will outline the UK's initiatives and the collaborative efforts needed to combat this global menace. Discussions will focus on enhancing international cooperation, harmonizing scam prevention efforts, and leveraging technology to protect consumers worldwide.Panel discussions on the first day will explore the urgent need for coordinated global action. Sessions will dive into the human cost of scams, share international lessons in scam prevention, and highlight the role of public-private partnerships in advancing fraud legislation and industry best practices. The main focus of the event is to foster cross-border and -sector collaborations.Industry Leaders to Drive Technological InnovationsThe summit will also feature contributions from tech giants and financial institutions, focusing on how cutting-edge technologies like AI can be utilized to thwart scammers effectively. Industry leaders will discuss the creation of the Global Signal Exchange, an innovative platform aimed at enhancing data sharing across borders to better track and prevent scams.Day two of GASS London 2025 will be dedicated to solutions-focused workshops and breakout sessions. Experts will present the latest advancements in scam detection and prevention, from deepfake recognition to strategies for securing digital identities. Interactive discussions will enable participants to share insights and develop actionable strategies for protecting consumers globally, such as the GASA recommendation that every country should have a dedicated national anti-scam centre.The event agenda and attendance tickets are available here: https://www.gasa.org/gass-2025-londonThe summit will look to solidify commitments from attending public and private organizations and set a roadmap for international cooperation through 2026 and beyond.GASS London 2025 is a call to action for every stakeholder in the fight against online fraud. It offers a unique opportunity to join forces with global leaders and take a stand against the cyber threats that impact millions of lives each year.Selected speakers include:Aad Lensen, Jeroen Niessen, and Ruben van Well, Dutch PoliceAndrei Skorobogatov, Home OfficeAngelique Miet, European CommissionBen Donaldson, UK FinanceDr Elizabeth Carter, Kingston University LondonEls Bruggeman, EuroconsumersHedwige Nuyens, International Banking Federation (IBFed)Henriette Bongers, FraudeHelpdesk.nlJayde Richmond, Australian National Anti-Scam CentreJean-Jacques Sahel, GoogleJorij Abraham, GASAKate Griffin, Aspen InstituteKitboga, YouTube ScambaiterLaura Kankaala, F-SecureLucia Harris, Match GroupLuke Reynolds, MastercardLynette Owens, Trend MicroMike Haley, CifasNatalie Black, OFCOMNathaniel Gleicher, MetaThe event agenda and attendance tickets are available here: https://www.gasa.org/gass-2025-londonContact InformationSam RogersMarketing Director, Global Anti-Scam Alliancesam.rogers@gasa.org+31 (0) 645 130 670Hayley PatersonPress & PR Manager, Cifashayley.paterson@cifas.org.ukRelated VideoSOURCE: Global Anti-Scam AllianceRelated Documents: Global State of Scams Report - 2024.pdfState of Scams in the United Kingdom Report - 2024.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics (GA) today announced the strategic acquisition of North Point Defense, Inc. (NPD), a leading provider of Signals Intelligence (SIGINT) exploitation software and sensor integration, by General Atomics Integrated Intelligence, Inc. (GA-III), formerly known as General Atomics Commonwealth Computer Research, Inc. This acquisition enhances GA's capabilities in the rapidly evolving SIGINT field, positioning the company to deliver advanced ISR solutions for air, sea, ground, and space platforms.The new Quadratix enterprise will bond GA's large software workforce and extensive suite of systems under a unified umbrella, merging solutions for: From concept to deployment, NPD delivers AI/ML-based autonomous signal processing and data dissemination solutions providing real-time actionable intelligence, supporting tactical and national mission priorities. "Joining GA represents an incredible opportunity to enhance our impact in delivering cutting-edge SIGINT solutions in support of national and tactical users," said Bruce Benenati, President of NPD. "As part of a mission-focused organization with a proven track-record in tactical intelligence across the DoD and IC, we can accelerate innovation and deployment at scale. The integration gives our team access to unmatched operational expertise, resources, and a broader customer base. Together, we are poised to deliver even greater capabilities to those who depend on us in the field."GA-III is committed to providing a comprehensive suite of "out-of-the-box" hardware and software tools to meet mission requirements and expand the innovative intelligence capabilities within the GA group of companies. "The integration of NPD technologies into a division of GA-III is a strategic shift, enhancing GA's ability to innovate rapidly and provide greater value to customers with end-to-end ISR solutions that are more efficient, effective, and technologically advanced." said Brian Ralston, President of GA-III.Baird served as the exclusive financial adviser and Miles & Stockbridge acted as legal counsel to North Point Defense on the transaction.About General Atomics and General Atomics Integrated IntelligenceGeneral Atomics is a defense and diversified technologies company, founded in 1955 as a division of General Dynamics and acquired by the Blue family in 1986. GA and affiliates operate on five continents, and produce unmanned aircraft and airborne sensor systems, satellite surveillance, high power laser, hypervelocity projectile, and power conversion systems. GA is a leader in nuclear fusion research, next-generation nuclear fission and advanced materials technologies. The company occupies 8+ million square feet of engineering, laboratory and manufacturing facilities and comprises over 13,000 employees.GA-III's capabilities include spatio-temporal data management, advanced analytics, visualization tools, and computer vision, alongside AI/ML-enabled automated target recognition services. These capabilities support a wide range of national, tactical, and commercial/international applications, leveraging both commercial cloud and edge-based computing solutions and are fully integrated with GA Aeronautical Systems' unmanned aircraft and airborne sensor systems.Media Contact: https://www.ga.com/general-business-inquiriesContact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

Visitor Registration is Now Open: www.analyticavietnam2025.events-regis.com/Two exhibition halls featuring the latest in laboratory technology, analysis, and biotech solutions.Over 300 exhibitors and brands from across the globe, offering cutting-edge products and innovations.New features like the Start-Up Pavilion, Live Lab Demo, Innovation Zone, and Lab Design & Construction Forum.HO CHI MINH CITY, VIETNAM, Mar 6, 2025 - (ACN Newswire via SeaPRwire.com) - analytica Vietnam 2025, the country’s largest and most influential trade fair for laboratory technology, analysis, and biotechnology, is set to return bigger than ever. Taking place from 2-4 April 2025 at the Saigon Exhibition and Convention Center (SECC), Ho Chi Minh City, this 8th edition will be the largest in the event’s history, expanding to two exhibition halls and welcoming over 300 exhibitors and brands, and 6,000 trade visitors from across the region.Endorsed by the Ministry of Science and Technology in Vietnam and supported by the National Agency for Science and Technology Information (NASATI), Center for Science and Technology Information (CESTI), Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, Federal Ministry for Economic Affairs and Climate Action of Germany, and the Association of Small & Medium Enterprises (Singapore), analytica Vietnam 2025 continues to uphold its reputation as a leading industry event.Global Participation and Networking OpportunitiesThis year’s edition will see extensive global participation, with dedicated pavilions from Germany, Singapore, and China, alongside exhibitors from Vietnam, Malaysia, Japan, South Korea, the UK, Switzerland, France, Spain, Turkey, India, and the USA. The event continues to serve as a premier platform for networking, innovation, and business development in the industry. Michael Wilton, Managing Director of MMI Asia, the organizer of analytica Vietnam, expressed, "The continuous growth of analytica Vietnam reflects the increasing demand for advanced laboratory and analytical solutions across Vietnam and the region. Expanding to two halls not only accommodates more exhibitors but also opens up new avenues for collaboration, knowledge exchange, and innovation. We’re excited to welcome professionals from all over the world to experience our largest and most comprehensive edition yet."What to Expect at analytica Vietnam 2025?Academic Conference: Learn from internationally renowned experts as they share research, trends, and findings on topics such as Environmental and Green Chemistry, Food and Quality Control, Pharmaceutical Analysis & Health Science, and Future Technologies.Live Lab Demo: This interactive feature brings advanced analytical instruments, automation, and testing procedures to life, allowing visitors to witness real-time applications across various industries.Innovation Zone: A dedicated area showcasing the newest and most groundbreaking products in laboratory technology, analysis, and biotech solutions.Lab 4.0 Exhibitor Forum: Explore a range of innovative technologies and solutions transforming laboratory operations. Topics will include automation, digitalization, advanced data analytics, new materials, and cutting-edge techniques in laboratory management and research.Lab Design and Construction Forum: Gain insights into the latest trends in lab design, energy-efficient solutions, sustainable practices, and innovative layouts. Industry experts and renowned speakers will share their expertise on creating modern laboratories that meet both functionality and environmental standards.Lucky Draw: Stand a chance to win exciting prizes sponsored by our esteemed exhibitors.Hosted Buyer Program: The largest program yet, with key buyers from Vietnam, Cambodia, Thailand, and Malaysia, invited for exclusive business meetings with exhibitors.Vincent Au Yeong, Country Manager of ITS Vietnam, the event’s Bronze Sponsor, shared, "As a customer of analytica Vietnam for nearly 10 years, I have witnessed the event’s growth and the valuable benefits it brings each year. The continuous development of analytica has reinforced our confidence in its ability to provide insights, foster partnerships, and stay ahead of industry trends. We’re proud to be part of this long-term journey and look forward to further growth together. We can’t wait to meet both our longtime and new customers here."Top 15 Products You Can Look Forward to Seeing at the Exhibition:1. Mixer Mill MM 400 by ITS2. PacBio Revio/Onso Sequencing System by DKSH3. Xevo MRT Mass Spectrometer by Waters4. Liquid Chromatograph Mass Spectrometer by Shimadzu5. epMotion 5075 by Eppendorf6. Biosafety cabinet, Tangerine by Oriental Giken7. High-Speed Amino Acid Analyzer LA8080 by 2H Instrument8. EMC Magnetic Cell Holder by EMCLAB Instruments GmbH9. Hot Head by ELDEX CORPORATION10. Gas generator for TOC Gas Analysis by cmc Instruments GmbH11. Sykam Amino Acid Analyzers by Hoa Viet Co., Ltd12. SCIEX ZenoTOF 7600 SCIEX ZenoTOF 7600 LC-MS/MS System Model: ZenoTOF 7600 by Viet Nguyen Co.,ltd13. Avio 550 ICP-OES - Perkin Elmer14. MIRI® Time-Lapse Incubat or by ESCO15. AI - RIDA®SMART APP Allergen (2024) by R-BiopharmBe Part of analytica Vietnam 2025 – Register Today!To make the most of your experience at analytica Vietnam 2025, we recommend that trade visitors register in advance. This will ensure seamless access to the event and provide updates on the latest developments. For more information and to complete your registration, please visit www.analyticavietnam2025.events-regis.com/About analytica Vietnamanalytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.About analytica worldwideMesse München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam, analytica USA, and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of worldleading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.comAbout Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twelve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Daniel ShiExhibition Directordaniel@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Joey NgMarketing Executivejoey@mmiasia.com.sg Copyright 2025 ACN Newswire via SeaPRwire.com.